Novartis loses cost decision in Zentiva patent dispute at UPC
MLex Summary: Pharmaceutical company Novartis today lost the decision on legal cost compensation in the dispute regarding EP 2,501,384 with Zentiva entities at the UPC’s central division in Milan, due to insufficient...To view the full article, register now.
Already a subscriber? Click here to view full article